News

Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy

/in , , , , /by

Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy The agreement combines Domain Therapeutics’ candidate DT-7012 with Chime Biologics’ internationally-recognized manufacturing expertise In June 2023, Domain nominated DT-7012, a Treg depleting anti-CCR8 monoclonal antibody (mAb) with best-in-class potential, which enters Phase I studies in 2025 The CCR8 GPCR […]

Read more

Mr. Huang Guo, Deputy Commissioner of China NMPA Visits Chime Biologics Wuhan Headquarter

/in , , , , /by

Mr. Huang Guo, Deputy Commissioner of China NMPA Visits Chime Biologics Wuhan Headquarter April 9, 2024, Wuhan, China – Chime Biologics, a leading global CDMO that enables its partners’ success in biologics, today is visited by Mr. Huang Guo, Deputy Commissioner of China NMPA with his delegation. Leaders from Hubei Medical Products Administration and Wuhan East Lake High-tech Development Zone […]

Read more